11 results on '"White, J. Michael"'
Search Results
2. Neoantigen-specific cytotoxic Tr1 CD4 T cells suppress cancer immunotherapy
- Author
-
Sultan, Hussein, Takeuchi, Yoshiko, Ward, Jeffrey P., Sharma, Naveen, Liu, Tian-Tian, Sukhov, Vladimir, Firulyova, Maria, Song, Yuang, Ameh, Samuel, Brioschi, Simone, Khantakova, Darya, Arthur, Cora D., White, J. Michael, Kohlmiller, Heather, Salazar, Andres M., Burns, Robert, Costa, Helio A., Moynihan, Kelly D., Yeung, Yik Andy, Djuretic, Ivana, Schumacher, Ton N., Sheehan, Kathleen C. F., Colonna, Marco, Allison, James P., Murphy, Kenneth M., Artyomov, Maxim N., and Schreiber, Robert D.
- Abstract
CD4+T cells can either enhance or inhibit tumour immunity. Although regulatory T cells have long been known to impede antitumour responses1–5, other CD4+T cells have recently been implicated in inhibiting this response6,7. Yet, the nature and function of the latter remain unclear. Here, using vaccines containing MHC class I (MHC-I) neoantigens (neoAgs) and different doses of tumour-derived MHC-II neoAgs, we discovered that whereas the inclusion of vaccines with low doses of MHC-II-restricted peptides (LDVax) promoted tumour rejection, vaccines containing high doses of the same MHC-II neoAgs (HDVax) inhibited rejection. Characterization of the inhibitory cells induced by HDVax identified them as type 1 regulatory T (Tr1) cells expressing IL-10, granzyme B, perforin, CCL5 and LILRB4. Tumour-specific Tr1 cells suppressed tumour rejection induced by anti-PD1, LDVax or adoptively transferred tumour-specific effector T cells. Mechanistically, HDVax-induced Tr1 cells selectively killed MHC-II tumour antigen-presenting type 1 conventional dendritic cells (cDC1s), leading to low numbers of cDC1s in tumours. We then documented modalities to overcome this inhibition, specifically via anti-LILRB4 blockade, using a CD8-directed IL-2 mutein, or targeted loss of cDC2/monocytes. Collectively, these data show that cytotoxic Tr1 cells, which maintain peripheral tolerance, also inhibit antitumour responses and thereby function to impede immune control of cancer.
- Published
- 2024
- Full Text
- View/download PDF
3. Fetal MAVS and type I IFN signaling pathways control ZIKV infection in the placenta and maternal decidua
- Author
-
Alippe, Yael, Wang, Leran, Coskun, Reyan, Muraro, Stéfanie P., Zhao, Fang R., Elam-Noll, Michelle, White, J. Michael, Vota, Daiana M., Hauk, Vanesa C., Gordon, Jeffrey I., Handley, Scott A., and Diamond, Michael S.
- Abstract
The contribution of placental immune responses to congenital Zika virus (ZIKV) syndrome remains poorly understood. Here, we leveraged a mouse model of ZIKV infection to identify mechanisms of innate immune restriction exclusively in the fetal compartment of the placenta. ZIKV principally infected mononuclear trophoblasts in the junctional zone, which was limited by mitochondrial antiviral-signaling protein (MAVS) and type I interferon (IFN) signaling mechanisms. Single nuclear RNA sequencing revealed MAVS-dependent expression of IFN-stimulated genes (ISGs) in spongiotrophoblasts but not in other placental cells that use alternate pathways to induce ISGs. ZIKV infection of Ifnar1−/− or Mavs−/− placentas was associated with greater infection of the adjacent immunocompetent decidua, and heterozygous Mavs+/− or Ifnar1+/− dams carrying immunodeficient fetuses sustained greater maternal viremia and tissue infection than dams carrying wild-type fetuses. Thus, MAVS-IFN signaling in the fetus restricts ZIKV infection in junctional zone trophoblasts, which modulates dissemination and outcome for both the fetus and the pregnant mother.
- Published
- 2024
- Full Text
- View/download PDF
4. MHC-II neoantigens shape tumour immunity and response to immunotherapy
- Author
-
Alspach, Elise, Lussier, Danielle M., Miceli, Alexander P., Kizhvatov, Ilya, DuPage, Michel, Luoma, Adrienne M., Meng, Wei, Lichti, Cheryl F., Esaulova, Ekaterina, Vomund, Anthony N., Runci, Daniele, Ward, Jeffrey P., Gubin, Matthew M., Medrano, Ruan F. V., Arthur, Cora D., White, J. Michael, Sheehan, Kathleen C. F., Chen, Alex, Wucherpfennig, Kai W., Jacks, Tyler, Unanue, Emil R., Artyomov, Maxim N., and Schreiber, Robert D.
- Abstract
The ability of the immune system to eliminate and shape the immunogenicity of tumours defines the process of cancer immunoediting1. Immunotherapies such as those that target immune checkpoint molecules can be used to augment immune-mediated elimination of tumours and have resulted in durable responses in patients with cancer that did not respond to previous treatments. However, only a subset of patients benefit from immunotherapy and more knowledge about what is required for successful treatment is needed2–4. Although the role of tumour neoantigen-specific CD8+T cells in tumour rejection is well established5–9, the roles of other subsets of T cells have received less attention. Here we show that spontaneous and immunotherapy-induced anti-tumour responses require the activity of both tumour-antigen-specific CD8+and CD4+T cells, even in tumours that do not express major histocompatibility complex (MHC) class II molecules. In addition, the expression of MHC class II-restricted antigens by tumour cells is required at the site of successful rejection, indicating that activation of CD4+T cells must also occur in the tumour microenvironment. These findings suggest that MHC class II-restricted neoantigens have a key function in the anti-tumour response that is nonoverlapping with that of MHC class I-restricted neoantigens and therefore needs to be considered when identifying patients who will most benefit from immunotherapy.
- Published
- 2019
- Full Text
- View/download PDF
5. Cancer immunoediting by the innate immune system in the absence of adaptive immunity
- Author
-
O’Sullivan, Timothy, Saddawi-Konefka, Robert, Vermi, William, Koebel, Catherine M., Arthur, Cora, White, J. Michael, Uppaluri, Ravi, Andrews, Daniel M., Ngiow, Shin Foong, Teng, Michele W.L., Smyth, Mark J., Schreiber, Robert D., and Bui, Jack D.
- Abstract
Cancer immunoediting is the process whereby immune cells protect against cancer formation by sculpting the immunogenicity of developing tumors. Although the full process depends on innate and adaptive immunity, it remains unclear whether innate immunity alone is capable of immunoediting. To determine whether the innate immune system can edit tumor cells in the absence of adaptive immunity, we compared the incidence and immunogenicity of 3′methylcholanthrene-induced sarcomas in syngeneic wild-type, RAG2−/−, and RAG2−/−x γc−/− mice. We found that innate immune cells could manifest cancer immunoediting activity in the absence of adaptive immunity. This activity required natural killer (NK) cells and interferon γ (IFN-γ), which mediated the induction of M1 macrophages. M1 macrophages could be elicited by administration of CD40 agonists, thereby restoring editing activity in RAG2−/−x γc−/− mice. Our results suggest that in the absence of adaptive immunity, NK cell production of IFN-γ induces M1 macrophages, which act as important effectors during cancer immunoediting.
- Published
- 2012
- Full Text
- View/download PDF
6. Blocking Monoclonal Antibodies Specific for Mouse IFN-αα/ββReceptor Subunit 1 (IFNAR-1) from Mice Immunized by In VivoHydrodynamic Transfection
- Author
-
Sheehan, Kathleen C.F., Lai, Koon Siew, Dunn, Gavin P., Bruce, Allen T., Diamond, Mark S., Heutel, Jennifer D., Dungo-Arthur, Corazon, Carrero, Javier A., White, J. Michael, Hertzog, Paul J., and Schreiber, Robert D.
- Abstract
Herein we report the generation of mouse monoclonal antibodies (mAbs) specific for the IFNAR-1 subunit of the mouse interferon-αα/ββ(IFN-αα/ββ) receptor (MAR1 mAbs) that block type I IFN receptor signaling and biologic response induction in vitroand in vivo. These mAbs were generated from Ifnar1––/––mice immunized by in vivohydrodynamic transfection with a plasmid encoding the extracellular domain (ECD) of murine IFNAR-1. All MAR1 mAbs bound native receptor expressed on cell surfaces and immunoprecipitated IFNAR-1 from solubilized cells, and two mAbs also detected IFNAR-1 by Western blot analysis. in vitro, the mAbs prevented ligand-induced intracellular signaling and induction of a variety of type I IFN-induced biologic responses but had no effect on IFN-γγ-induced responses. The most effective in vitroblocker, MAR1-5A3, also blocked type I IFN-induced antiviral, antimicrobial, and antitumor responses in vivo. We also explored whether murine IFNAR-1 surface expression required the presence of Tyk2. In contrast to Tyk2-deficient human cell lines, comparable IFNAR-1 expression was found on primary cells derived either from wild-type or Tyk2––/––mice. These mAbs represent much needed tools to more clearly elucidate the biochemistry, cell biology, and physiologic function of the type I IFNs and their receptor in mediating host-protective immunity and immunopathology.
- Published
- 2006
- Full Text
- View/download PDF
7. Friend of GATA-1 Represses GATA-3–dependent Activity in CD4+ T Cells
- Author
-
Zhou, Meixia, Ouyang, Wenjun, Gong, Qian, Katz, Samuel G., White, J. Michael, Orkin, Stuart H., and Murphy, Kenneth M.
- Abstract
The development of naive CD4+ T cells into a T helper (Th) 2 subset capable of producing interleukin (IL)-4, IL-5, and IL-13 involves a signal transducer and activator of transcription (Stat)6-dependent induction of GATA-3 expression, followed by Stat6-independent GATA-3 autoactivation. The friend of GATA (FOG)-1 protein regulates GATA transcription factor activity in several stages of hematopoietic development including erythrocyte and megakaryocyte differentiation, but whether FOG-1 regulates GATA-3 in T cells is uncertain. We show that FOG-1 can repress GATA-3–dependent activation of the IL-5 promoter in T cells. Also, FOG-1 overexpression during primary activation of naive T cells inhibited Th2 development in CD4+ T cells. FOG-1 fully repressed GATA-3–dependent Th2 development and GATA-3 autoactivation, but not Stat6-dependent induction of GATA-3. FOG-1 overexpression repressed development of Th2 cells from naive T cells, but did not reverse the phenotype of fully committed Th2 cells. Thus, FOG-1 may be one factor capable of regulating the Th2 development.
- Published
- 2001
- Full Text
- View/download PDF
8. Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody ABX-CBL
- Author
-
Deeg, H. Joachim, Blazar, Bruce R., Bolwell, Brian J., Long, Gwynn D., Schuening, Friedrich, Cunningham, John, Rifkin, Robert M., Abhyankar, Sunil, Briggs, Adrienne D., Burt, Richard, Lipani, John, Roskos, Lorin K., White, J. Michael, Havrilla, Nancy, Schwab, Gisela, and Heslop, Helen E.
- Abstract
ABX-CBL, an immunoglobulin M murine monoclonal antibody, recognizes CD147 and initiates cell killing through complement-mediated lysis. In a dose-finding trial, 27 patients with steroid-refractory acute graft-versus-host disease (GVHD) received ABX-CBL at 0.01 (presumed no effect dose), 0.1, 0.2, or 0.3 mg/kg per day, and an additional 32 patients were given ABX-CBL at 0.2 or 0.15 mg/kg per day. All patients had undergone allogeneic transplantation for malignant or nonmalignant disorders and received GVHD prophylaxis, generally with methotrexate- and cyclosporine-containing regimens. None responded to methylprednisolone, given for a minimum of 3 days. ABX-CBL was started 20 to 236 (median, 47) days after transplantation; it was given for 7 consecutive days and was followed by 2 infusions per week for 2 more weeks. Among 51 patients evaluable for efficacy, 26 (51%) responded, including 13 with complete responses (CR) and 13 with partial responses (PR). CR lasting 14 days or longer or PR lasting 7 days or longer occurred in 21 (41%; 8 CR, 13 PR) patients, including 19 of 43 (44%) patients who received 0.1 to 0.3 mg/kg ABX-CBL and 2 of 8 (25%) patients given 0.01 mg/kg per day. Myalgias at doses 0.2 mg/kg or greater were dose limiting and resolved without sequelae. Causes of death included organ failure, progressive GVHD, and infection. No death was attributed to ABX-CBL. At 6 months after the initiation of ABX-CBL therapy, 26 (44%) patients were surviving. These results are encouraging. Further studies on the use of ABX-CBL in the management of GVHD are warranted.
- Published
- 2001
- Full Text
- View/download PDF
9. Single-Cell Analysis of Neonatal HSC Ontogeny Reveals Gradual and Uncoordinated Transcriptional Reprogramming that Begins before Birth
- Author
-
Li, Yanan, Kong, Wenjun, Yang, Wei, Patel, Riddhi M., Casey, Emily B., Okeyo-Owuor, Theresa, White, J. Michael, Porter, Shaina N., Morris, Samantha A., and Magee, Jeffrey A.
- Abstract
Fetal and adult hematopoietic stem cells (HSCs) have distinct proliferation rates, lineage biases, gene expression profiles, and gene dependencies. Although these differences are widely recognized, it is not clear how the transition from fetal to adult identity is coordinated. Here we show that murine HSCs and committed hematopoietic progenitor cells (HPCs) undergo a gradual, rather than precipitous, transition from fetal to adult transcriptional states. The transition begins prior to birth and is punctuated by a late prenatal spike in type I interferon signaling that promotes perinatal HPC expansion and sensitizes progenitors to the leukemogenic FLT3ITDmutation. Most other changes in gene expression and enhancer activation are imprecisely timed and poorly coordinated. Thus, heterochronic enhancer elements, and their associated transcripts, are activated independently of one another rather than as part of a robust network. This simplifies the regulatory programs that guide neonatal HSC/HPC ontogeny, but it creates heterogeneity within these populations.
- Published
- 2020
- Full Text
- View/download PDF
10. A Randomized, Open-Label, Multicenter, Dose Escalation Study of HQK-1001 (2,2-Dimethylbutyrate, Sodium Salt) in Sickle Cell Disease
- Author
-
Kutlar, Abdullah, Reid, Marvin, Taher, Ali T, Inati, Adlette, Abboud, Miguel R., El-Beshlawy, Amal, Buchanan, George R., Smith, Hedy, Ataga, Kenneth I., Koshy, Nebu, Neumayr, Lynne D, Malik, Punam, Alvarez, Ofelia A., Ward, Richard, White, J Michael, Johnson, Elsa, and Ghalie, Richard G.
- Abstract
Kutlar: HemaQuest Pharmaceuticals, Inc.: Research Funding. Reid:Haemaquest: Honoraria. Taher:Novartis: Research Funding, Speakers Bureau. Abboud:Novartis: Speakers Bureau; Pfizer: Research Funding; Sangart: Membership on an entity's Board of Directors or advisory committees. Buchanan:HemaQuest Pharmacuetical, Inc.: Research Funding. Ataga:HemaQuest Pharmaceuticals, Inc: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding. White:HemaQuest: Consultancy. Johnson:HemaQuest Pharmaceuticals: Employment, Equity Ownership. Ghalie:HemaQuest Pharmaceuticals: Employment, Equity Ownership.
- Published
- 2012
- Full Text
- View/download PDF
11. A Phase 2 Clinical Study of HQK-1001 (2,2-dimethylbutyrate, sodium salt), a Fetal Hemoglobin Inducer, in Patients with Sickle Cell Disease
- Author
-
Kutlar, Abdullah, Inati, Adlette, Taher, Ali T, El-Beshlawy, Amal, Reid, Marvin, Abboud, Miguel R., Smith, Hedy, Ataga, Kenneth I., Buchanan, George R., Malik, Punam, Koshy, Nebu, Neumayr, Lynne, Aiello, Maria, Johnson, Elsa, White, J Michael, and Ghalie, Richard G.
- Abstract
Aiello: HemaQuest Pharmaceuticals: Employment. Johnson:HemaQuest Pharmaceuticals: Employment. White:HemaQuest Pharmaceuticals: Consultancy. Ghalie:HemaQuest Pharmaceuticals: Employment.
- Published
- 2011
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.